HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shulkin, B. L. Articles by Hutchinson, R. J. Search for Related Content PubMed PubMed Citation Articles by Shulkin, B. L. Articles by Hutchinson, R. J.

Iodine-131-Metaiodobenzylguanidine and Bone Scintigraphy for the Detection of Neuroblastoma

Division of Nuclear Medicine, Department of Internal Medicine, Department of Pediatrics and Communicable Diseases, University of Michigan Mott Children's Hospital, Ann Arbor, Michigan

Correspondence: For reprints contact: Barry Shulkin, MD, Pediatric Nuclear Medicine, University of Michigan Medical Center, MCHC F3341 Box 0229, Ann Arbor, MI 48109.

ABSTRACT

The purpose of this study was to compare the utility of bone and metaiodobenzylguanidine (MIBG) scintigraphy for the detection of primary and metastatic deposits of neuroblastoma. ^99mTc methylene diphosphonate (MDP) bone and ¹³¹I-MIBG scans performed within 1 mo of each other in 85 patients with known or suspected neuroblastoma were evaluated for evidence of skeletal and extraskeletal disease. In 77 of 77 patients with confirmed neuroblastoma, the MDP and MIBG scans were concordant for the presence or absence of skeletal disease. A nearly twofold greater number of skeletal lesions were evident on MIBG scanning. No patients with normal bone scans had MIBG studies indicating bone involvement. In patients with histologic evidence of bone marrow involvement, each study suggested skeletal lesions in approximately 70%. In patients with extraskeletal disease demonstrated by CT, there was soft-tissue uptake of MIBG in 80% and MDP in 39%. We conclude that both MIBG and MDP are useful for the detection of skeletal neuroblastoma. MIBG is the better agent for characterizing the extent of disease, and MDP is a valuable adjunctive agent that provides skeletal landmarks for comparison. MIBG is clearly superior for the detection of extraskeletal neuroblastoma.

This article has been cited by other articles:

				S Basu and N Nair Stable disease and improved health-related quality of life (HRQoL) following fractionated low dose 131I-metaiodobenzylguanidine (MIBG) therapy in metastatic paediatric paraganglioma: observation on false "reverse" discordance during pre-therapy work up and its implication for patient selection for high dose targeted therapy Br. J. Radiol., August 1, 2006; 79(944): e53 - e58. [Abstract] [Full Text] [PDF]

				K. K. Matthay, J. C. Tan, J. G. Villablanca, G. A. Yanik, J. Veatch, B. Franc, E. Twomey, B. Horn, C. P. Reynolds, S. Groshen, et al. Phase I Dose Escalation of Iodine-131-Metaiodobenzylguanidine With Myeloablative Chemotherapy and Autologous Stem-Cell Transplantation in Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium Study J. Clin. Oncol., January 20, 2006; 24(3): 500 - 506. [Abstract] [Full Text] [PDF]

				F. D. Pashankar, M. S. O'Dorisio, and Y. Menda MIBG and Somatostatin Receptor Analogs in Children: Current Concepts on Diagnostic and Therapeutic Use J. Nucl. Med., January 1, 2005; 46(1_suppl): 55S - 61S. [Abstract] [Full Text] [PDF]

				B. H. Kushner Neuroblastoma: A Disease Requiring a Multitude of Imaging Studies J. Nucl. Med., July 1, 2004; 45(7): 1172 - 1188. [Abstract] [Full Text] [PDF]

				K. Hahn, M. Charron, B. L. Shulkin, M. J. Siegel, and F. A. Hoffer Role of MR Imaging and Iodine 123 MIBG Scintigraphy in Staging of Pediatric Neuroblastoma [letter] * Drs Siegel and Hoffer respond: Radiology, June 1, 2003; 227(3): 908 - 909. [Full Text] [PDF]

				B. H. Kushner, S. D.J. Yeh, K. Kramer, S. M. Larson, and N.-K. V. Cheung Impact of Metaiodobenzylguanidine Scintigraphy on Assessing Response of High-Risk Neuroblastoma to Dose-Intensive Induction Chemotherapy J. Clin. Oncol., March 15, 2003; 21(6): 1082 - 1086. [Abstract] [Full Text] [PDF]

				G. J. Lonergan, C. M. Schwab, E. S. Suarez, and C. L. Carlson From the Archives of the AFIP : Neuroblastoma, Ganglioneuroblastoma, and Ganglioneuroma: Radiologic-Pathologic Correlation RadioGraphics, July 1, 2002; 22(4): 911 - 934. [Abstract] [Full Text] [PDF]

				G. A. Yanik, J. E. Levine, K. K. Matthay, J. C. Sisson, B. L. Shulkin, B. Shapiro, D. Hubers, S. Spalding, T. Braun, J. L.M. Ferrara, et al. Pilot Study of Iodine-131-Metaiodobenzylguanidine in Combination With Myeloablative Chemotherapy and Autologous Stem-Cell Support for the Treatment of Neuroblastoma J. Clin. Oncol., April 15, 2002; 20(8): 2142 - 2149. [Abstract] [Full Text] [PDF]

				M. J. Siegel, H. Ishwaran, B. D. Fletcher, J. S. Meyer, F. A. Hoffer, D. Jaramillo, R. J. Hernandez, S. E. Roubal, B. A. Siegel, D. J. Caudry, et al. Staging of Neuroblastoma at Imaging: Report of the Radiology Diagnostic Oncology Group Radiology, April 1, 2002; 223(1): 168 - 175. [Abstract] [Full Text] [PDF]

				B. H. Kushner, H. W.D. Yeung, S. M. Larson, K. Kramer, and N.-K. V. Cheung Extending Positron Emission Tomography Scan Utility to High-Risk Neuroblastoma: Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography as Sole Imaging Modality in Follow-Up of Patients J. Clin. Oncol., July 15, 2001; 19(14): 3397 - 3405. [Abstract] [Full Text] [PDF]